argenx SE (ARGNF)
OTCMKTS · Delayed Price · Currency is USD
814.94
+20.34 (2.56%)
At close: Feb 12, 2026
argenx SE Revenue
In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth. argenx SE had revenue of $1.32B in the quarter ending December 31, 2025, with 73.69% growth.
Revenue
4.25B
Revenue Growth
+88.63%
P/S Ratio
10.72
Revenue / Employee
2.66M
Employees
1,599
Market Cap
45.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.65% |
| Dec 31, 2012 | 4.00M | 11.07K | 0.28% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 115.29K |
argenx SE News
- 13 hours ago - Argenx (ARGX) Upgraded by Deutsche Bank with Increased Price Target - GuruFocus
- 1 day ago - Wedbush Reiterates Outperform Rating for argenx (ARGX) with $1000 Price Target | ARGX Stock News - GuruFocus
- 5 days ago - argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline - GlobeNewsWire
- 5 days ago - Oversold Conditions For argenx (ARGX) - Nasdaq
- 6 days ago - Here's How Much $100 Invested In argenx 5 Years Ago Would Be Worth Today - Benzinga
- 8 days ago - argenx SE at TD Cowen Healthcare Conference Transcript - GuruFocus
- 11 days ago - RBC Capital Lowers Price Target for argenx (ARGX) Amidst Maintained 'Outperform' Rating | ARGX ... - GuruFocus
- 11 days ago - Wells Fargo Lowers Price Target for argenx (ARGX) but Maintains Overweight Rating | ARGX Stock News - GuruFocus